Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/10/22
Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10thGlobeNewsWire • 11/01/22
Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome PatientsGlobeNewsWire • 10/18/22
Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical StudyGlobeNewsWire • 09/13/22
Quoin Pharmaceuticals, Ltd. (QNRX) CEO Michael Myers on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/18/22
Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/18/22
Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18thGlobeNewsWire • 08/11/22
Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public OfferingGlobeNewsWire • 08/05/22
Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply AgreementsGlobeNewsWire • 07/15/22
Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in CanadaPRNewsWire • 07/15/22
Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical StudyGlobeNewsWire • 07/06/22
Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewsWire • 06/15/22
Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater ChinaGlobeNewsWire • 06/15/22
Quoin Pharmaceuticals: On Track to Deliver the First FDA-Approved Treatment for Netherton SyndromeNewsfile Corp • 05/17/22